Clinical Trials Directory

Trials / Completed

CompletedNCT04224246

Impact of Gamma-OH on Sleep in ICU Patients

Impact of Gamma-OH on Sleep in ICU Patients Difficult to Wean from Mechanical Ventilation

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
20 (actual)
Sponsor
Poitiers University Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The Main objective of the trial is to assess sleep quality with Gamma-OH® in patients difficult to wean from mechanical ventilation in the ICU.

Conditions

Interventions

TypeNameDescription
DRUGGamma HydroxybutyrateGamma-OH® will be administered intravenously at a dose of 20 mg/kg/h for 6 hours

Timeline

Start date
2020-02-27
Primary completion
2023-02-09
Completion
2023-02-09
First posted
2020-01-13
Last updated
2025-02-20

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04224246. Inclusion in this directory is not an endorsement.

Impact of Gamma-OH on Sleep in ICU Patients (NCT04224246) · Clinical Trials Directory